Dacetuzumab
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Humanized (from mouse) |
Target | CD40 |
Clinical data | |
Other names | SGN-40 |
ATC code |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
UNII | |
Chemical and physical data | |
Formula | C6452H9964N1732O1998S42 |
Molar mass | 145,100 g/mol (for the peptide) g·mol−1 |
![]() ![]() |
Dacetuzumab (also known as SGN-40 or huS2C6) is a humanized monoclonal antibody[1] being developed for the treatment of CD40-positive cancers like non-Hodgkin's lymphoma[2] and hematological malignancies.[3]
This drug was developed by Seattle Genetics, Inc.
References[]
- ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Dacetuzumab, American Medical Association.
- ^ Advani R, Forero-Torres A, Furman RR, Rosenblatt JD, Younes A, Ren H, et al. (September 2009). "Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin's lymphoma". Journal of Clinical Oncology. 27 (26): 4371–7. doi:10.1200/JCO.2008.21.3017. PMID 19636010.
- ^ Khubchandani S, Czuczman MS, Hernandez-Ilizaliturri FJ (June 2009). "Dacetuzumab, a humanized mAb against CD40 for the treatment of hematological malignancies". Current Opinion in Investigational Drugs. 10 (6): 579–87. PMID 19513947.
Categories:
- Drugs not assigned an ATC code
- Monoclonal antibodies for tumors
- Experimental drugs
- Monoclonal antibody stubs
- Antineoplastic and immunomodulating drug stubs